Extracellular vesicles (EVs) and their cargo represent an intriguing source of cancer biomarkers for developing robust and sensitive molecular tests by liquid biopsy. Prostate cancer (PCa) is still one of the most frequent and deadly tumor in men and analysis of EVs from biological fluids of PCa patients has proven the feasibility and the unprecedented potential of such an approach. Here, we exploited an antibody-based proteomic technology, i.e. the Reverse-Phase Protein microArrays (RPPA), to measure key antigens and activated signaling in EVs isolated from sera of PCa patients. Notably, we found tumor-specific protein profiles associated with clinical settings as well as candidate markers for EV-based tumor diagnosis. Among others, PD-L1, ERG, Integrin-β5, Survivin, TGF-β, phosphorylated-TSC2 as well as partners of the MAP-kinase and mTOR pathways emerged as differentially expressed endpoints in tumor-derived EVs. In addition, the retrospective analysis of EVs from a 15-year follow-up cohort generated a protein signature with prognostic significance. Our results confirm that serum-derived EV cargo may be exploited to improve the current diagnostic procedures while providing potential prognostic and predictive information. The approach proposed here has been already applied to tumor entities other than PCa, thus proving its value in translational medicine and paving the way to innovative, clinically meaningful tools.

Signore, M., Alfonsi, R., Federici, G., Nanni, S., Addario, A., Bertuccini, L., Aiello, A., Di Pace, A. L., Sperduti, I., Muto, G., Giacobbe, A., Collura, D., Brunetto, L., Simone, G., Costantini, M., Crino, L., Rossi, S., Tabolacci, C., Diociaiuti, M., Merlino, T., Gallucci, M., Sentinelli, S., Papalia, R., De Maria, R., Bonci, D., Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancer, <<CELL DEATH & DISEASE>>, 2021; 12 (7): 636-N/A. [doi:10.1038/s41419-021-03909-z] [http://hdl.handle.net/10807/183046]

Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancer

Alfonsi R.;Nanni S.;Aiello A.;De Maria R.
Ultimo
;
2021

Abstract

Extracellular vesicles (EVs) and their cargo represent an intriguing source of cancer biomarkers for developing robust and sensitive molecular tests by liquid biopsy. Prostate cancer (PCa) is still one of the most frequent and deadly tumor in men and analysis of EVs from biological fluids of PCa patients has proven the feasibility and the unprecedented potential of such an approach. Here, we exploited an antibody-based proteomic technology, i.e. the Reverse-Phase Protein microArrays (RPPA), to measure key antigens and activated signaling in EVs isolated from sera of PCa patients. Notably, we found tumor-specific protein profiles associated with clinical settings as well as candidate markers for EV-based tumor diagnosis. Among others, PD-L1, ERG, Integrin-β5, Survivin, TGF-β, phosphorylated-TSC2 as well as partners of the MAP-kinase and mTOR pathways emerged as differentially expressed endpoints in tumor-derived EVs. In addition, the retrospective analysis of EVs from a 15-year follow-up cohort generated a protein signature with prognostic significance. Our results confirm that serum-derived EV cargo may be exploited to improve the current diagnostic procedures while providing potential prognostic and predictive information. The approach proposed here has been already applied to tumor entities other than PCa, thus proving its value in translational medicine and paving the way to innovative, clinically meaningful tools.
Inglese
Signore, M., Alfonsi, R., Federici, G., Nanni, S., Addario, A., Bertuccini, L., Aiello, A., Di Pace, A. L., Sperduti, I., Muto, G., Giacobbe, A., Collura, D., Brunetto, L., Simone, G., Costantini, M., Crino, L., Rossi, S., Tabolacci, C., Diociaiuti, M., Merlino, T., Gallucci, M., Sentinelli, S., Papalia, R., De Maria, R., Bonci, D., Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancer, <>, 2021; 12 (7): 636-N/A. [doi:10.1038/s41419-021-03909-z] [http://hdl.handle.net/10807/183046]
File in questo prodotto:
File Dimensione Formato  
41419_2021_Article_3909.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 5.93 MB
Formato Adobe PDF
5.93 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/183046
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 6
social impact